Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Clinical trial NCT04498832 · COMPLETED

Trial details

NCT number: NCT04498832
Sponsor: Sanofi Pasteur, a Sanofi Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Influenza Immunization Healthy Volunteers

Start date: 2020-10-21
Primary completion: 2021-01-14
Enrollment: 2100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.